| Protocols | ||
|---|---|---|
| 7 protocol(s) meet the specified criteria | ||
| Disease Site: Unknown Sites | ||
| Protocol No. | Title | Status |
| 2843-1001 | A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects with Relapsed/Refractory Advanced and/or Metastatic Solid Tumors | Open |
| ANHL1522 | A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) | Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| C-145-03 | A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck | Open |
| FADOI03-2016 | Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio Study | Open |
| NANT17-01/MIBG-D | A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory Neuroblastoma | Open |
| NCI-10057-CIRB | A Phase II Study of Talimogene Iaherparepvec Followed by Talimogene Iaherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors | Open |